Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOAET3)

• Drug Name: Autologous T-cell therapy Drug Info
• Synonyms: Anti-PSMA designer T cells, Roger Williams; Gene therapy (chimeric anti-PSMA antibody-TCR), Roger Williams; Autologous T-cell therapy (anti-PSMA-CD3, prostate cancer); Autologous T-cell therapy (anti-PSMA-CD3, prostate cancer), Roger Williams Medical Center; Retrovirus-based ex vivo gene therapy (anti-PSMA-CD3, prostate cancer), Roger Williams Medical Center

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMOAET3

Molecule-Related Drug Atlas

Drug(s) Targeting T-cell surface glycoprotein CD3 gamma (CD3G)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tebentafusp	DMUJ1WV	Gastric cancer	2B72	Approved	[3]
Teplizumab	DMZ3P6C	Type-1 diabetes	5A10	Approved	[4]
Ertumaxomab	DM5Z3VP	Breast cancer	2C60-2C65	Phase 2	[5]
MGD007	DMAHWLR	Colorectal cancer	2B91.Z	Phase 1/2	[6]
MT-110	DMPCUN5	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
MEDI-565	DMFWPLQ	Gastrointestinal cancer	2C11	Phase 1	[6]

Drug(s) Targeting T-cell surface glycoprotein CD3 epsilon (CD3E)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Muromonab	DM8ANCF	Organ transplant rejection	NE84	Approved	[8]
Ertumaxomab	DM5Z3VP	Breast cancer	2C60-2C65	Phase 2	[5]
Resimmune	DMT5QSD	Cutaneous T-cell lymphoma	2B01	Phase 2	[9]
MT-110	DMPCUN5	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]

Drug(s) Targeting Glutamate carboxypeptidase II (GCPII)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capromab	DMHERIJ	Prostate cancer	2C82.0	Approved	[10]
PSMA-11 Ga-68	DMWLTU2	Diagnostic imaging	N.A.	Approved	[11]
Lutetium Lu-177 vipivotide tetraxetan	DMQ0IZ6	Prostate cancer	2C82.0	Approved	[12]
177-Lu-PSMA-617	DMX178V	Prostate cancer	2C82.0	Phase 3	[13]
BAY 2315497	DMUHH2G	Prostate cancer	2C82.0	Phase 3	[14]
J 591 Lu-177	DM9XKJU	Prostate cancer	2C82.0	Phase 2	[15]
G-202	DMQR9I8	Adenocarcinoma	2D40	Phase 2	[16]
ATL101	DMYAQV2	Influenza virus infection	1E30-1E32	Phase 2	[17]
99mTc-MIP-1404	DML4GU1	Prostate cancer	2C82.0	Phase 2	[18]
MLN-591RL	DMJHVZC	Prostate cancer	2C82.0	Phase 2	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glutamate carboxypeptidase II (GCPII)	TT9G4N0	FOLH1_HUMAN	Not Available	[2]
T-cell surface glycoprotein CD3 epsilon (CD3E)	TTZAT79	CD3E_HUMAN	Not Available	[2]
T-cell surface glycoprotein CD3 gamma (CD3G)	TTV3XPL	CD3G_HUMAN	Not Available	[2]

References

• [1] Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunology. 2014 May 16;3(5):e16.
• [2] Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
• [6] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [7] EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74.
• [8] Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs. 2003;63(24):2803-35.
• [9] Resimmune, an anti-CD3 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.Haematologica.2015 Jun;100(6):794-800.
• [10] Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med. 2007 Jan;37(1):17-28.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [12] [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]. Nuklearmedizin. 2016 Jun 28;55(3):123-8.
• [13] Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer. Cureus. 2020 Jun 30;12(6):e8921.
• [14] ClinicalTrials.gov (NCT03724747) Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer. U.S. National Institutes of Health.
• [15] Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013 Sep 15;19(18):5182-91.
• [16] National Cancer Institute Drug Dictionary (drug id 666090).
• [17] Clinical pipeline report, company report or official report of Atlab pharma.
• [18] 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013 Aug;54(8):1369-76.
• [19] Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Res. 2015 Apr 29;5:28.